We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · November 04, 2021

Vedolizumab and Anti-TNFα Outcomes in Biologic-Naïve Patients With IBD

Journal of Crohn's & Colitis


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Crohn's & Colitis
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
J Crohns Colitis 2021 Oct 07;15(10)1694-1706, B Bressler, A Yarur, MS Silverberg, M Bassel, E Bellaguarda, C Fourment, A Gatopoulou, P Karatzas, U Kopylov, G Michalopoulos, S Michopoulos, U Navaneethan, DT Rubin, J Siffledeen, A Singh, K Soufleris, D Stein, D Demuth, GJ Mantzaris

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading